CKDX.F Stock Overview
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Opthea Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.29 |
| 52 Week High | AU$0.42 |
| 52 Week Low | AU$0.29 |
| Beta | 0.68 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -80.92% |
| 5 Year Change | n/a |
| Change since IPO | -47.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| CKDX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 0.3% |
| 1Y | n/a | 2.9% | 24.2% |
Return vs Industry: Insufficient data to determine how CKDX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CKDX.F performed against the US Market.
Price Volatility
| CKDX.F volatility | |
|---|---|
| CKDX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CKDX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CKDX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 24 | Fred Guerard | opthea.com |
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema.
Opthea Limited Fundamentals Summary
| CKDX.F fundamental statistics | |
|---|---|
| Market cap | US$237.86m |
| Earnings (TTM) | -US$142.52m |
| Revenue (TTM) | US$385.28k |
617.4x
P/S Ratio-1.7x
P/E RatioIs CKDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CKDX.F income statement (TTM) | |
|---|---|
| Revenue | US$385.28k |
| Cost of Revenue | US$166.83k |
| Gross Profit | US$218.45k |
| Other Expenses | US$142.74m |
| Earnings | -US$142.52m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 56.70% |
| Net Profit Margin | -36,992.04% |
| Debt/Equity Ratio | -1,463.5% |
How did CKDX.F perform over the long term?
See historical performance and comparison